Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Danuglipron and Ervogastat in Healthy and Overweight Adults
NCT04839393Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danuglipron and ervogastat in obesity and Overweight (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration (Cmax) of danuglipron at Day 1, Area Under the Curve (AUC24) of danuglipron at Day 1 and 3 more. Started Apr 2021; status: completed.
02
Drugs
danuglipronervogastat
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04839393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839393.